Dorothy Puhy - Dec 22, 2022 Form 4 Insider Report for ABIOMED INC (NASD)

Role
Director
Signature
/s/ Michael Dube (by power of attorney)
Stock symbol
NASD
Transactions as of
Dec 22, 2022
Transactions value $
$0
Form type
4
Date filed
12/27/2022, 07:44 PM
Previous filing
Aug 12, 2022
Next filing
Feb 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NASD Common Stock, $0.01 par value Disposed to Issuer $0 -3.26K -100% $0.00* 0 Dec 22, 2022 Direct F1, F2, F3
transaction NASD Common Stock, $0.01 par value Disposed to Issuer $0 -11.3K -100% $0.00* 0 Dec 22, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Dorothy Puhy is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (the "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement.
F2 Pursuant to the Merger Agreement, each award of restricted stock units, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the effective time of the Merger (the "Effective Time") was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share underlying such Company RSU Award immediately prior to the Effective Time.
F3 Reflects the correction of an immaterial error in the balance reported in the reporting person's Form 4 filed on August 12, 2022.